FISCHER MEDICAL VENTURES LIMITED
Unaudited Standalone and Consolidated Financial Results for Quarter Ended 30.06.2025
Date of Board Meeting: 14 August 2025
1. Auditor’s Note
- Standalone and Consolidated Results have been reviewed by M/s Bilimoria Mehta & Co., Chartered Accountants.
- The review was conducted under SRE 2410 (Review of Interim Financial Information).
- No qualifications, concerns, or issues were raised by the auditors.
- The auditor’s opinion is unmodified, confirming compliance with Ind AS 34 and SEBI (LODR) Regulations, 2015.
- Reliance on other auditors for subsidiaries and associates is noted, with no modifications to opinion.
Conclusion: Auditor’s reports are clean with no qualifications or adverse remarks.
2. Financial Performance
| Particulars | Standalone Q1 FY26 (30.06.2025) | Standalone Q4 FY25 (31.03.2025) | Standalone Q1 FY25 (30.06.2024) | Standalone FY25 (31.03.2025) | Standalone FY24 (31.03.2024) | Consolidated Q1 FY26 (30.06.2025) | Consolidated Q3 FY25 (31.12.2024) | Consolidated Q1 FY25 (30.06.2024) | Consolidated FY25 (31.03.2025) | Consolidated FY24 (31.03.2024) |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations (Rs. Lakhs) | 454.23 | 521.97 | - | 521.97 | 1,152.83 | (Not provided for Q1) | 4,917.42 | 1,012.07 | 11,069.87 | 2,098.13 |
| Other Income (Rs. Lakhs) | 80.40 | 64.94 | 112.23 | 345.70 | 75.05 | (Not provided for Q1) | 14.87 | 74.17 | 149.20 | 50.11 |
| Total Income (Rs. Lakhs) | 534.63 | 586.90 | 112.23 | 867.67 | 1,227.88 | 3,091.11 | 4,932.29 | 1,086.25 | 11,219.07 | 2,148.25 |
| Total Expenses (Rs. Lakhs) | 556.19 | 700.05 | 11.28 | 771.59 | 1,174.01 | 2,062.43 | 4,740.75 | 1,069.92 | 10,948.15 | 1,937.14 |
| Profit / (Loss) Before Exceptional Items & Tax (Rs. Lakhs) | (21.56) | (113.15) | 100.95 | 96.08 | 53.87 | 1,028.68 | 191.54 | 16.32 | 270.92 | 211.11 |
| Exceptional Items (Rs. Lakhs) | - | - | - | - | - | (11.26) | (8.79) | (5.11) | (35.36) | - |
| Share of Profit/(Loss) of Associates (Rs. Lakhs) | 0 | 0 | 0 | 0 | 0 | 0.11 | (1.53) | (3.61) | (13.29) | - |
Notes:
- EPS and margins are not explicitly provided in the filing.
- Revenue for Standalone Q1 FY25 (30.06.2024) is not available.
- Consolidated Q1 FY26 revenue from operations is not explicitly stated for quarter ended 30.06.2025 but total income is given.
- Consolidated revenue and total income show significant growth in FY25 compared to FY24.
- Standalone results show a loss before tax in Q1 FY26 and Q4 FY25, but a profit in Q1 FY25 and FY25 full year.
- Consolidated results show profit before tax in all periods, with a dip in Q3 FY25 but strong full year FY25 performance.
3. Detailed Notes / Management Commentary
- No explicit management commentary or explanatory notes on financial results are provided in the filing.
- No changes in accounting policies, material adjustments, or caveats are mentioned.
- No specific commentary on financial services metrics such as AUM, NPAs, slippages, or margins.
- The company has announced the resignation of an Independent Director, Dr. Jacob Thomas, effective 14 August 2025, with no material reasons other than personal.
- Appointment of new Secretarial Auditors for a five-year term was approved.
- No mention of material adjustments or restatements.
4. Segment Information
- No explicit segment-wise financial breakdown is provided in the filing.
- However, the consolidated results include multiple subsidiaries and associates across geographies (India, Philippines, Singapore, Malaysia).
- List of subsidiaries and associates provided (Annexure-1), including:
- Time Medical International Ventures (India) Pvt Ltd (100%)
- Time Medical Philippines (75%)
- Blusim tech Pte Ltd (20% associate)
- The Therapy Platform Pte Ltd (20% associate)
- Flynncare HealthCare Innovations Pvt Ltd (100%)
- Wondertech Medical Solutions Pvt Ltd (51%)
- Fischer Hospitality Sdn. Bdn. (60%)
- FMV International Ventures PTE Ltd (100%)
- FMV HealthCare PTE Ltd (100%)
- FMV Global Innovation PTE Ltd (100%)
5. Capex, Projects, and Corporate Activity
- No explicit details on capital expenditure (capex), ongoing or planned projects, or strategic initiatives are provided.
- No mention of writedowns, writebacks, impairments, or provisions.
- No acquisitions, disposals, divestitures, or mergers announced in this filing.
- Corporate activity includes:
- Resignation of Independent Director Dr. Jacob Thomas (effective 14 August 2025).
- Appointment of M/s Nuren Lodaya & Associates as Secretarial Auditors for five years.
- No restructuring or cost-cutting measures disclosed.
6. Standalone vs Consolidated
- Both Standalone and Consolidated financial results are provided.
- Standalone results show lower revenue and losses in recent quarters.
- Consolidated results show significantly higher revenue and profits, reflecting contributions from subsidiaries and associates.
- Consolidated total assets of subsidiaries as at 30 June 2025: Rs. 41,539.12 Lakhs.
- Consolidated year-to-date total revenues: Rs. 3,091.11 Lakhs.
- Consolidated year-to-date total comprehensive income: Rs. 500.82 Lakhs.
Summary for Investment Analysis Team
| Aspect | Key Points |
|---|---|
| Auditor’s Note | Clean review reports with no qualifications or concerns for both standalone and consolidated. |
| Financial Performance | - Standalone Q1 FY26 revenue: Rs. 454.23 Lakhs; loss before tax Rs. (21.56) Lakhs. |
| - Consolidated Q1 FY26 total income: Rs. 3,091.11 Lakhs; profit before tax Rs. 1,028.68 Lakhs. | |
| - FY25 consolidated revenue Rs. 11,069.87 Lakhs vs Rs. 2,098.13 Lakhs in FY24 (strong growth). | |
| - Standalone FY25 revenue Rs. 521.97 Lakhs vs Rs. 1,152.83 Lakhs in FY24 (decline). | |
| Management Commentary | No significant commentary or changes in accounting policies. |
| Segment Information | No detailed segment financials; multiple subsidiaries and associates across geographies. |
| Capex & Corporate Activity | No capex or project details; resignation of Independent Director; appointment of Secretarial Auditors. |
| Standalone vs Consolidated | Consolidated results significantly stronger than standalone, reflecting group operations. |
No EPS or margin data provided; recommend follow-up for detailed profitability metrics and segment performance.